Emile Nuwaysir, BlueRock CEO
May 27, 2021 07:41 AM EDTUpdated May 28, 01:23 PM
Deals
Cell/Gene Tx

Look­ing to build new smart cells, Blue­Rock teams with Tim Lu's Sen­ti Bio in 'sec­ond-or­der' en­gi­neer­ing al­liance

Jason Mast

Editor

Blue­Rock, the Ver­sant-backed and Bay­er-owned biotech best known for its Parkin­son’s cell ther­a­py, has been qui­et­ly lay­ing out much grander plans for their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times